Targeted topical and combination laser surgery for the treatment of angiofibromas

Lasers in Surgery and Medicine

Volumn 45, Issue 9, 2013, Pages 555-557

  Bae Harboe, Yoon Soo Cindy ^a   Geronemus, Roy G ^a  

^a LASER AND SKIN SURGERY CENTER OF NEW YORK   (United States)

Author keywords

angiofibromas; laser; pulsed dye; resurfacing; sirolimus; tuberous sclerosis

Indexed keywords

RAPAMYCIN;

ABLATIVE FRACTIONAL RESURFACING; ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CASE REPORT; ELECTROSURGERY; ESTHETIC SURGERY; FACE; FEMALE; HEMANGIOFIBROMA; HUMAN; PATIENT SAFETY; PRIORITY JOURNAL; PULSED DYE LASER; RISK BENEFIT ANALYSIS; SKIN DEFECT; TREATMENT OUTCOME; TUBEROUS SCLEROSIS;

ANGIOFIBROMAS; LASER; PULSED DYE; RESURFACING; SIROLIMUS; TUBEROUS SCLEROSIS;

ADULT; ANGIOFIBROMA; ANTIBIOTICS, ANTINEOPLASTIC; COMBINED MODALITY THERAPY; ELECTROSURGERY; FACIAL NEOPLASMS; FEMALE; HUMANS; LASERS, DYE; SIROLIMUS; TUBEROUS SCLEROSIS;

EID: 84886076179     PISSN: 01968092     EISSN: 10969101     Source Type: Journal    
DOI: 10.1002/lsm.22189     Document Type: Article

References (10)

1. Hofbauer GF, Marcollo-Pini A, Corsenca A, Kistler AD, French LE, Wüthrich RP, Serra AL,. The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis. Br J Dermatol 2008; 159 (2): 473-475.
2. Pasyk KA, Argenta LC,. Argon laser surgery of skin lesions in tuberous sclerosis. Ann Plast Surg 1988; 20 (5): 426-433.
3. Bellack GS, Shapshay SM,. Management of facial angiofibromas in tuberous sclerosis: Use of the carbon dioxide laser. Otolaryngol Head Neck Surg 1986; 94 (1): 37-40.
4. Weiss ET, Geronemus RG,. New technique using combined pulse dye laser and fractional resurfacing for the treating facial angiofibromas in tuberous sclerosis. Lasers Surg Med 2010; 42 (5): 357-360.
5. Li S, Takeuchi F, Wang JA, Fan Q, Komurasaki T, Billings EM, Pacheco-Rodriguez G, Moss J, Darling TN,. Mesenchymal-epithelial interactions involving epiregulin in tuberous sclerosis complex hamaratomas. PNAS 2008; 105: 3539-3544.
6. Bissler JJ, McCormack FX, Young LR, et al. Rapamycin for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008; 358: 140-151.
7. Franz DN, Leonard J, Tudor C, et al. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol 2006; 59: 490-498.
8. Koenig MK, Butler IJ, Northrup H,. Regression of subependymal giant cells astrocytoma with rapamycin in tuberous sclerosis complex. J Child Neurol 2008; 23: 1238-1239.
9. Glasgow CG, Steagall WK, Taveira-DaSilva A, et al. Lymphangioleiomyomatosis (LAM): Molecular insights lead to targeted therapies. Respir Med 2010; 104: S45-S58.
10. Koenig MK, Herber AA, Roberson J, Samuels J, Slopis J, Woerner A, Northup H,. Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: A double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycin. Drugs R D 2012; 12 (3): 121-126.